FOLFOX4 plus Cetuximab for Patients with previously untreated metastatic colorectal cancer according to tumour RAS and BRAF mutation status: updated Analysis of the CECOG/CORE 1.2.002 study

Klaus Kaczirek, Tudor E. Ciuleanu, Damir Vrbanec, Erika Marton, Diethelm Messinger Bernadette Liegl-Atzwanger, Fritz Wrba, Regina Knittelfelder, Elisabeth Lindner, Christoph Zielinski, Berthold Streubel,   Thomas Brodowicz

ClinCC Volume 14, Nr 2, June 2015, 91-98

CORE 2FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

T. Brodowicz, T. E. Ciuleanu, D. Radosavljevic, E. Shacham-Shmueli, D. Vrbanec, S. Plate, Z. Mrsic-Krmpotic, M. Dank, G. Purkalne, D. Messinger, and C. C. Zielinski

Ann Oncol (2013) 24 (7): 1769-1777 first published online April 4, 2013

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.

Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC.

World J Gastroenterol. 2010 Jul 7;16(25):3133-43.

A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX-6 + Cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients with metastatic colorectal cancer.

T. Ciuleanu, G. Kurteva, J. Ocvirk, S. Beslija, I. Koza, D. Papamichael, D. Vrbanec, T. Brodowicz, W. Scheithauer, C. Zielinski

J. Clin. Oncol (supplement to 26) 2008: #4032

Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial

Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E. Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

Journal of Clinical Oncology, 2007,25: 2212-2217

Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial–SAKK 44/00-CECOG/PAN.1.3.001.

Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group.

J Clin. Oncol. 2008 Aug 1;26(22): 3695-701

Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophago-gastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001.

Hejna M, Raderer M, Zacherl J, Ba-Ssalamah A, Püspök A, Pluschnig U, Brodowicz T, Zielinski C.

Anti-Cancer Drugs, 2008, 19:535-539

Consensus on the Medical Treatment of Colon Cancer

Kornek G, Scheithauer W, Anghel R, Bodoky G, Ciardiello F, Ciuleanu T, Glynne-Jones R, Grünberger T, Koza I, Ocvirk J, Petruzelka L, Poston G, Ramadori G, Schmiegel W, Segaert S, Tabernero J, Zwierzina H, Zielinski C.

Memo (2008) Vol.1: 79-90

For publications of the results of the Consensus Conferenences
see Consensus Statements »

Prof. Zielinski on Publications

CECOG Contact Information

Please feel free to contact us if you have any questions.

  • by phone: +43/1/409 77 25

  • christiane.thallinger@cancer-center.cc

  • or fill in the form on contact page